Abstract
AbbVie will report its quarterly results on February 04, 2026 Pre-Market; this preview synthesizes recent financial performance, current-quarter forecasts, and leading institutional commentary to frame expectations and likely stock drivers.
Market Forecast
For the current quarter, AbbVie’s internal forecast points to revenue of $16.43 billion, with estimated year-over-year growth of 10.71%. Forecasted EBIT is $6.21 billion with an estimated year-over-year increase of 15.68%, and estimated EPS is $2.64 with an estimated year-over-year growth of 24.62%. The company’s main businesses continue to center around Immunology and Neuroscience, with expectations for stable gross profit margin and improving net profit margin alongside adjusted EPS expansion; year-over-year comparisons suggest stronger operating leverage this quarter.
Within AbbVie’s portfolio, Immunology remains the core growth engine, while Neuroscience is a notable contributor; the most promising segment in consensus commentary is Immunology, supported by scale and product breadth, with segment revenue of $7.89 billion last quarter and improving year-over-year trajectory inferred from current-quarter forecasts.
Last Quarter Review
In the previous quarter, AbbVie recorded revenue of $15.78 billion, a gross profit margin of 71.75%, GAAP net profit attributable to the parent company of $1.86 million, a net profit margin of 1.18%, and adjusted EPS of $1.86, with revenue growing 9.10% year over year and adjusted EPS declining 38.00% year over year. Quarter-on-quarter net profit attributable to the parent company decreased by 80.17%, reflecting transitional dynamics and one-time items relative to operating performance.
A key highlight was sustained strength in core operating profitability, evidenced by a 71.75% gross margin that underscores strong product mix and pricing power. Main business highlights included Immunology revenue of $7.89 billion, Neuroscience revenue of $2.84 billion, Oncology revenue of $1.68 billion, Medical Aesthetics revenue of $1.19 billion, and Other Major Products revenue of $1.01 billion, which together indicate a diversified base with resilient category performance.
Current Quarter Outlook
Main Business: Immunology
Immunology remains AbbVie’s centerpiece, anchored by mature franchises and newer assets that collectively drive scale, margin stability, and cash generation. The last quarter’s $7.89 billion revenue footprint in Immunology provides a robust base from which current-quarter acceleration can materialize, supported by the forecasted total company revenue growth of 10.71%. Management’s revenue and EPS estimates imply improving operating leverage, which often correlates with consistent demand across key autoimmune indications. The anticipated EBIT growth of 15.68% points to favorable mix and disciplined expense control, a tailwind for gross margin retention near historical levels. Close monitoring of volume trends and pricing dynamics within Immunology should inform whether current momentum is sustainable, with upside skew if prescription growth and patient adherence track ahead of historical averages.
Most Promising Business: Neuroscience
Neuroscience has established itself as a meaningful contributor with last quarter’s $2.84 billion revenue, demonstrating scale and breadth that complement AbbVie’s Immunology anchor. As EPS is estimated to grow 24.62% year over year, Neuroscience’s margin profile and operating efficiency can provide incremental leverage, especially if utilization patterns and formulary positioning remain supportive. The segment’s performance benefits from ongoing adoption across neurology indications, translating to steady revenue cadence and potential upside if new patient starts perform well in the quarter. Analysts have highlighted Neuroscience’s role in diversifying earnings streams, which buffers the portfolio against category-specific headwinds and supports the consolidated forecast that points to double-digit revenue growth.
Stock Price Drivers This Quarter
This quarter’s stock performance will likely pivot on EPS delivery versus the $2.64 estimate and revenue relative to the $16.43 billion forecast, with gross margin quality and net margin trajectory serving as key validation points. The prior quarter’s 71.75% gross margin sets a high benchmark, and maintaining a comparable level would validate the product mix narrative that underpins EBIT growth of 15.68%. Visibility on net profit margin improvement from the previous quarter’s 1.18% will be essential; positive inflection should reinforce confidence in operating normalization and conversion from top-line strength to bottom-line efficiency. Investors will also parse segment disclosures, particularly Immunology and Neuroscience, for evidence of sustained demand, pipeline execution, and any signals that support the forecasted year-over-year growth rates embedded in the company’s financial outlook.
Analyst Opinions
Recent institutional commentary skews bullish. Notable Buy reiterations include Evercore ISI (Gavin Clark-Gartner, price target $222.00), Guggenheim (Vamil Divan, price target $242.00), Cantor Fitzgerald (Carter Gould, price target $250.00), Wells Fargo (Mohit Bansal, price target $260.00), Leerink Partners (Jeffrey La Rosa and David Risinger, price targets around the mid-$240.00 range), and William Blair (Matt Phipps, Buy rating). Hold or Neutral stances have been maintained by Bernstein (Courtney Breen, price targets of $203.00 and $225.00 across recent notes) and Bank of America (Neutral, price target revised to $233.00), but these are in the minority relative to Buy recommendations collected within the period from October 28, 2025 to January 20, 2026. The ratio of bullish to bearish or neutral views is favorable to the bullish side, with Buy ratings substantially outnumbering Hold or Neutral calls over the last six months, indicating constructive expectations into the print.
The predominant Buy-side narrative emphasizes the durability of AbbVie’s revenue base, the improving EPS trajectory signaled by the $2.64 estimate with 24.62% year-over-year growth, and operating leverage implied in the $6.21 billion EBIT forecast. Analysts view Immunology’s scale as supportive of near-term growth while Neuroscience contributes diversification and margin support, aligning with the forecasted revenue of $16.43 billion and double-digit growth profile. The bullish majority expects management to deliver results consistent with guidance and current consensus levels, with upside optionality tied to segment mix and operating efficiency. A minority of neutral voices point to pipeline timing and valuation considerations, but the overall institutional stance remains tilted toward an optimistic outcome this quarter, focusing on EPS execution, margin quality, and reaffirmation of full-year outlooks.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments